Clinica study comparing HMVP and MVP regimens in the treatment of advanced non-small cell lung cancer
- VernacularTitle:HMVP与MVP方案治疗晚期非小细胞肺癌的临床研究
- Author:
Jianfei GAO
;
Changsheng LI
;
Guangzu DU
- Publication Type:Journal Article
- Keywords:
non-small cell lung cancer(NSCLC);
chemotherapy;
mitomycin C(MMC);
hydroxycamptothecin(HCPT);
vindesine(VDS);
cisplatin(DDP)
- From:China Oncology
2001;0(03):-
- CountryChina
- Language:Chinese
-
Abstract:
0.05). No significant differences were detected in the median time of remission, median survival time and 1-, 2-year survival rates between the groups. Moreover, no significant differences were detected in the grade Ⅲ～Ⅳ leukopenia, grade Ⅲ～Ⅳ thrombocytopenia, grade Ⅲ～Ⅳ nausea and vomiting and grade Ⅲ～Ⅳ constipation between the groups. Conclusions:The response rate of the MVP regimen is slightly lower than the HMVP regimen, but the HMVP regimen is not noticeably superior. It may increase the toxicity such as leukopenia, nausea/vomiting and constipation, as wellas being more expensive. In short, MVP regimen should be selected between the regimens in the chemotherapy of advanced NSCLC.
